These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21547395)

  • 21. First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma.
    Wen PY; Cloughesy TF; Olivero AG; Morrissey KM; Wilson TR; Lu X; Mueller LU; Coimbra AF; Ellingson BM; Gerstner E; Lee EQ; Rodon J
    Clin Cancer Res; 2020 Apr; 26(8):1820-1828. PubMed ID: 31937616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
    Karavasilis V; Kotoula V; Pentheroudakis G; Televantou D; Lambaki S; Chrisafi S; Bobos M; Fountzilas G
    J Neurol; 2013 Jun; 260(6):1469-80. PubMed ID: 23292205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
    Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
    Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
    Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.
    Broniscer A; Jia S; Mandrell B; Hamideh D; Huang J; Onar-Thomas A; Gajjar A; Raimondi SC; Tatevossian RG; Stewart CF
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27035. PubMed ID: 29512900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
    Broniscer A; Baker SJ; Stewart CF; Merchant TE; Laningham FH; Schaiquevich P; Kocak M; Morris EB; Endersby R; Ellison DW; Gajjar A
    Clin Cancer Res; 2009 Jan; 15(2):701-7. PubMed ID: 19147777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.
    Galanis E; Buckner JC; Maurer MJ; Reid JM; Kuffel MJ; Ames MM; Scheithauer BW; Hammack JE; Pipoly G; Kuross SA
    Invest New Drugs; 2005 Oct; 23(5):495-503. PubMed ID: 16133802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.
    Schwer AL; Damek DM; Kavanagh BD; Gaspar LE; Lillehei K; Stuhr K; Chen C
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):993-1001. PubMed ID: 17967517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
    Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
    Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
    Omuro A; Chan TA; Abrey LE; Khasraw M; Reiner AS; Kaley TJ; Deangelis LM; Lassman AB; Nolan CP; Gavrilovic IT; Hormigo A; Salvant C; Heguy A; Kaufman A; Huse JT; Panageas KS; Hottinger AF; Mellinghoff I
    Neuro Oncol; 2013 Feb; 15(2):242-50. PubMed ID: 23243055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas.
    Kreisl TN; Kotliarova S; Butman JA; Albert PS; Kim L; Musib L; Thornton D; Fine HA
    Neuro Oncol; 2010 Feb; 12(2):181-9. PubMed ID: 20150385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of GRN1005 in recurrent malignant glioma.
    Drappatz J; Brenner A; Wong ET; Eichler A; Schiff D; Groves MD; Mikkelsen T; Rosenfeld S; Sarantopoulos J; Meyers CA; Fielding RM; Elian K; Wang X; Lawrence B; Shing M; Kelsey S; Castaigne JP; Wen PY
    Clin Cancer Res; 2013 Mar; 19(6):1567-76. PubMed ID: 23349317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
    Desjardins A; Reardon DA; Peters KB; Threatt S; Coan AD; Herndon JE; Friedman AH; Friedman HS; Vredenburgh JJ
    J Neurooncol; 2011 Dec; 105(3):601-6. PubMed ID: 21735117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.
    Manley PE; Trippett T; Smith AA; Macy ME; Leary SES; Boklan J; Cohen KJ; Goldman S; Kilburn LB; Dhall G; Devin J; Herzog CE; Partap S; Fauchet F; Badreddine E; Bernard JP; Chi SN
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27217. PubMed ID: 29750396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.
    Santisteban M; Buckner JC; Reid JM; Wu W; Scheithauer BW; Ames MM; Felten SJ; Nikcevich DA; Wiesenfeld M; Jaeckle KA; Galanis E;
    J Neurooncol; 2009 Apr; 92(2):165-75. PubMed ID: 19066728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
    Clarke JL; Molinaro AM; Cabrera JR; DeSilva AA; Rabbitt JE; Prey J; Drummond DC; Kim J; Noble C; Fitzgerald JB; Chang SM; Butowski NA; Taylor JW; Park JW; Prados MD
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):603-610. PubMed ID: 28233053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
    Lee EQ; Puduvalli VK; Reid JM; Kuhn JG; Lamborn KR; Cloughesy TF; Chang SM; Drappatz J; Yung WK; Gilbert MR; Robins HI; Lieberman FS; Lassman AB; McGovern RM; Xu J; Desideri S; Ye X; Ames MM; Espinoza-Delgado I; Prados MD; Wen PY
    Clin Cancer Res; 2012 Nov; 18(21):6032-9. PubMed ID: 22923449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.
    Nagane M; Nishikawa R; Narita Y; Kobayashi H; Takano S; Shinoura N; Aoki T; Sugiyama K; Kuratsu J; Muragaki Y; Sawamura Y; Matsutani M
    Jpn J Clin Oncol; 2012 Oct; 42(10):887-95. PubMed ID: 22844129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas.
    Shi W; Palmer JD; Werner-Wasik M; Andrews DW; Evans JJ; Glass J; Kim L; Bar-Ad V; Judy K; Farrell C; Simone N; Liu H; Dicker AP; Lawrence YR
    J Neurooncol; 2016 May; 127(3):535-9. PubMed ID: 26821711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
    Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
    Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.